Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
Myriad Genetics (MYGN) announced a groundbreaking study validating a new polygenic risk score (PRS) for breast cancer risk assessment across all ancestries. The research, involving over 275,000 women, will be presented at the ASCO Annual Meeting on June 4, 2021. The updated PRS tool, offered at no extra cost through the myRisk Hereditary Cancer test, integrates over 90 genetic markers, enhancing personalized risk evaluations. This initiative aims to improve accessibility and reduce healthcare disparities in genetic testing.
- Validated PRS for breast cancer risk assessment in women across all ancestries.
- Study involves over 275,000 participants, reinforcing data credibility.
- Enhanced riskScore tool provided at no additional cost with myRisk testing.
- Myriad to launch standalone consumer version of riskScore in 2022, expanding access.
- None.
Study Is First to Validate New Polygenic Risk Assessment for All; Company Aims to Improve Access and Reduce Disparities in Genetic Testing
SALT LAKE CITY, May 19, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will present results from a study with more than 275,000 women validating the use of a new method for polygenic breast cancer risk assessments in women of all ancestries. The new data will be shared in an oral presentation with leading collaborators on June 4 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
“The polygenic risk score (PRS) is one of the most powerful risk prediction tools in the field of breast cancer, and until now a validated model had not been available to assess women of all ancestries,” said Holly Pederson, M.D., director of Medical Breast Services at Cleveland Clinic and presenter of the study. “Our data now provide a framework for a PRS that delivers a personalized genomic breast cancer risk assessment to any and all interested women. The updated PRS, validated and well-calibrated, may be the most exciting clinical development in risk stratification since multi-gene panel testing.”
Myriad Genetics currently offers its riskScore® PRS tool to women at no additional cost as part of the market-leading Myriad myRisk® Hereditary Cancer test. riskScore provides more comprehensive, personalized and actionable insight for women who qualify for myRisk. It incorporates more than 90 validated genetic markers and offers a precise estimate of a 5-year and lifetime risk to develop breast cancer.
“With this new study (abstract #10502), we are taking an important step to expand the ability of riskScore to benefit more women, making it the industry’s most inclusive breast cancer risk assessment PRS tool,” said Nicole Lambert, president of Myriad Genetic Laboratories. “Myriad Genetics is the first to validate a PRS for women of all ancestries. This reinforces our mission to advance health and wellbeing for all and reduce healthcare disparities.”
According to the American Cancer Society, the average risk of a woman in the United States to develop breast cancer in her lifetime is about
“These new findings will empower more women to take control of their health and enable healthcare providers to better diagnose and treat patients,” said Thomas Slavin, M.D., senior vice president of Medical Affairs for Oncology at Myriad Genetics and a co-author of the new validation study. “Tools such as PRS can help clinicians and patients make more informed decisions about how to manage their precise breast cancer risk.”
Myriad Genetics plans to launch riskScore for all ancestries later this year as part of its myRisk clinical test. In addition, the company recently announced plans to launch a standalone consumer version of riskScore in 2022. The consumer version will further expand riskScore access to a new population of 93 million women who do not already qualify for hereditary cancer testing due to their personal or family history.
Follow Myriad Genetics on Twitter via @myriadgenetics and keep up to date with ASCO 2021 meeting news and updates by using the #ASCO21 hashtag.
About riskScore
riskScore for all ancestries is a clinically validated precision medicine tool that enhances the Myriad myRisk Hereditary Cancer test. The test incorporates data from more than 90 single nucleotide polymorphisms identified through 20 years of genome wide association studies in breast cancer. It previously was validated to predict breast cancer risk in women of European descent and is now validated for all ancestries. This data is then combined with a personal and family history algorithm, the Tyrer-Cuzick model, to provide an individualized breast cancer risk assessment.
About Myriad myRisk Hereditary Cancer
The Myriad myRisk Hereditary Cancer test uses advanced technologies and proprietary algorithms to evaluate 35 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, EndoPredict, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the results and impact of a new study that validates the use of a new method for polygenic breast cancer risk assessments in women of all ancestries; the study helping more women take control of their health by understanding their risk of developing breast cancer; the expansion of the Company’s current riskScore offering to all women who meet clinical criteria and qualify for hereditary cancer testing, regardless of ancestry; the Company’s plan to launch a standalone consumer version of riskScore in 2022; and the Company’s strategic directives under the caption "About Myriad Genetics." These “forward-looking statements” are based on management's current expectations of future e
FAQ
What is the significance of the new polygenic risk score announced by Myriad Genetics (MYGN)?
When will Myriad Genetics present the results of their breast cancer risk assessment study?
How many women participated in the Myriad Genetics breast cancer risk study?
What features does the riskScore tool provide?
What future plans does Myriad Genetics have for the riskScore tool?
